Clinical and Genetic Classification of Osteogenesis Imperfecta and Epidemiology - Osteogenesis Imperfecta - page 19

[13] Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM.

Classiication of osteogenesis imperfecta revisited. Eur J Med
Genet 2010;53(1):1-5.

involve exon 6 in the COL1A1 and COL1A2 genes of type I col-
lagen. Am J Med Genet 1997;72(1):94-105.

[31] Tang BL. ADAMTS: a novel family of extracellular matrix prote-

ases. Int J Biochem Cell Biol 2001;33(1):33-44. [14] Kelley BP, Malfait F, Bonafe L, Baldridge D, Homan E,

Symoens S, et al. Mutations in FKBP10 cause recessive osteo-
genesis imperfecta and Bruck syndrome. J Bone Miner Res
2011;26(3):666-72.

[32] Cabral WA, Makareeva E, Colige A, Letocha AD, Ty JM, Yeowell

HN, et al. Mutations near amino end of alpha1(I) collagen cause
combined osteogenesis imperfecta/Ehlers-Danlos syndrome
by interference with N-propeptide processing. J Biol Chem
2005;281(19):19259-69.

[15] Pyott SM, Schwarze U, Christiansen HE, Pepin MG, Leistritz

DF, Dineen R, et al. Mutations in PPIB (cyclophilin B) delay type
I procollagen chain association and result in perinatal lethal to
moderate osteogenesis imperfecta phenotypes. Hum Mol Genet
2011;15(20):1595-609.

[33] Hopkins DR, Keles S, Greenspan DS. The bone morphoge-

netic protein 1/Tolloid-like metalloproteinases. Matrix Biol
2007;26(7):508-23.

[16] Warman ML, Cormier-Daire V, Hall C, Krakow D, Lachman R,

LeMerrer M, et al. Nosology and classiication of genetic skeletal
disorders: 2010 revision. Am J Med Genet A 2011;155A(5):
943-68.

[34] Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS.

Bone morphogenetic protein-1: the type I procollagen
C-proteinase. Science 1996;271(5247):360-2.

[35] Li SW, Sieron AL, Fertala A, Hojima Y, Arnold WV, Prockop DJ.

The C-proteinase that processes procollagens to ibrillar collagens
is identical to the protein previously identiied as bone morpho-
genic protein-1. Proc Natl Acad Sci USA 1996;93(10):5127-30.

[17] Becker J, Semler O, Gilissen C, Li Y, Bolz HJ, Giunta C, et al.

Exome sequencing identiies truncating mutations in human
SERPINF1 in autosomal-recessive osteogenesis imperfecta. Am
J Hum Genet 2011;88(3):362-71. [36] Martínez-Glez V, Valencia M, Caparrós-Martín JA, Aglan M,

Temtamy S, Tenorio J, et al. Identiication of a mutation causing
deicient BMP1/mTLD proteolytic activity in autosomal reces-
sive osteogenesis imperfecta. Hum Mutat 2012;33(2):343-50.

[18] Homan EP, Rauch F, Grafe I, Lietman C, Doll JA, Dawson B,

et al. Mutations in SERPINF1 cause osteogenesis imperfecta
type VI. J Bone Miner Res 2011;26(12):2798-803.

[19] Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives

on osteogenesis imperfecta. Nat Rev Endocrinol 2011;7(9):540-57.

[37] Pace JM, Wiese M, Drenguis AS, Kuznetsova N, Leikin S,

Schwarze U, et al. Defective C-propeptides of the proalpha2(I)
chain of type I procollagen impede molecular assembly and result
in osteogenesis imperfecta. J Biol Chem 2008;288(23):16061-7.

[20] Barnes AM, Cabral WA, Weis M, Makareeva E, Mertz EL,

Leikin S, et al. Absence of FKBP10 in recessive type XI osteogen-
esis imperfecta leads to diminished collagen cross-linking and
reduced collagen deposition in extracellular matrix. Hum Mutat
2012;33:1589-98.

[38] Chipman SD, Sweet HO, McBride DJJ, Davisson MT, Marks SCJ,

Shuldiner AR, et al. Defective pro alpha 2(I) collagen synthesis
in a recessive mutation in mice: a model of human osteogenesis
imperfecta. Proc Natl Acad Sci USA 1993;90(5):1701-5. [21] Volodarsky M, Markus B, Cohen I, Staretz-Chacham O, Flusser

H, Landau D, et al. A deletion mutation in TMEM38B associated
with autosomal recessive osteogenesis imperfecta. Hum Mutat
2013;34(4):582-6.

[39] Campbell BG, Wootton JA, Macleod JN, Minor RR. Canine

COL1A2 mutation resulting in C-terminal truncation of pro-
alpha2(I) and severe osteogenesis imperfecta. J Bone Miner Res
2001;16(6):1147-53. [22] Fahiminiya S, Majewski J, Mort J, Moffatt P, Glorieux FH, Rauch

F. Mutations in WNT1 are a cause of osteogenesis imperfecta.
J Med Genet 2013;50(5):345-8.

[40] Nicholls AC, Osse G, Schloon HG, Lenard HG, Deak S, Myers

JC, et al. The clinical features of homozygous alpha 2(I) collagen
deicient osteogenesis imperfecta. J Med Genet 1984;21(4):257-62. [23] Cho TJ, Lee KE, Lee SK, Song SJ, Kim KJ, Jeon D, et al. A single

recurrent mutation in the 5′-UTR of IFITM5 causes osteogenesis
imperfecta type V. Am J Hum Genet 2012;91(2):343-8.

[41] de Vries WN, de Wet WJ. The molecular defect in an autosomal

dominant form of osteogenesis imperfecta. Synthesis of type I
procollagen containing cysteine in the triple-helical domain of
pro-alpha 1(I) chains. J Biol Chem 1986;261(19):9056-64.

[24] Semler O, Garbes L, Keupp K, Swan D, Zimmermann K,

Becker J, et al. A mutation in the 5′-UTR of IFITM5 creates an in-
frame start codon and causes autosomal-dominant osteogenesis
imperfecta type V with hyperplastic callus. Am J Hum Genet
2012;91(2):349-57.

[42] Wynne-Davies R, Gormley J. Clinical and genetic patterns in

osteogenesis imperfecta. Clin Orthop Relat Res 1981;159:26-35.

[43] Donnelly DE, McConnell V, Paterson A, Morrison PJ. The preva-

lence of thanatophoric dysplasia and lethal osteogenesis imper-
fecta type II in Northern Ireland - a complete population study.
Ulster Med J 2010;79(3):114-8.

[25] Shapiro JR, Lietman C, Grover M, Lu JT, Nagamani S, Dawson BC,

et al. Phenotypic variability of osteogenesis imperfecta type V caused
by IFITM5 mutations. Osteoporos Int 2013. [epub ahead of print].

[26] Rauch F, Moffatt P, Cheung M, Roughley P, Lalic L, Lund AM,

et al. Osteogenesis imperfecta type V: marked phenotypic vari-
ability despite the presence of the IFITM5 c.-14C>T mutation
in all patients. J Med Genet 2013;50(1):21-4.

[44] Tan KL. Tock EPC. Osteogenesis imperfecta congenita. Aust

Paediat J 1971;7:49-53.

[45] Robert JM, Gremeau JL, Notter A, Guilhot J. Hereditary bone

fragility. Lyon Medical 1968;219:881-982.

[27] Vanleene M, Porter A, Guillot PV, Boyde A, Oyen M, Shefelbine

S. Ultra-structural defects cause low bone matrix stiffness
despite high mineralization in osteogenesis imperfecta mice.
Bone 2012;50(6):1317-23.

[46] Navani SV, Sarzin B. Intrauterine osteogenesis imperfecta.

review of the literature and a report of the radiological and nec-
ropsy indings in two cases. British J Radiol 1967;40:449-52.

[47] Stevenson DA, Carey JC, Byrne JL, Srisukhumbowornchai S,

Feldkamp ML. Analysis of skeletal dysplasias in the Utah popu-
lation. Am J Med Genet A 2012;158A(5):1046-54.

[28] Lindahl K, Barnes AM, Fratzl-Zelman N, Whyte MP, Hefferan

TE, Makareeva E, et al. COL1 C-propeptide cleavage site muta-
tions cause high bone mass osteogenesis imperfecta. Hum
Mutat 2011;32(6):598-609.

[48] Venturi G, Gandini A, Monti E, Dalle Carbonare L, Corradi M,

Vincenzi M, et al. Lack of expression of SERPINF1, the gene
coding for pigment epithelium-derived factor, causes progres-
sively deforming osteogenesis imperfecta with normal type I
collagen. J Bone Miner Res 2012;27(3):723-8.

[29] Becker U, Timpl R. NH2-terminal extensions on skin collagen

from sheep with a genetic defect in conversion of procollagen
into collagen. Biochemistry 1976;15(13):2853-62.

[30] Byers PH, Duvic M, Atkinson M, Robinow M, Smith LT, Krane

SM, et al. Ehlers-Danlos syndrome type VIIA and VIIB result
from splice-junction mutations or genomic deletions that

[49] Barbosa-Buck CO, Orioli IM, da Graça Dutra M, Lopez-Camelo J,

Castilla EE, Cavalcanti DP. Clinical epidemiology of skeletal dys-
plasias in South America. Am J Med Genet A 2012;158A(5):1038-45.